Skip to content

Clinical Observation of Guyuan Moxibustion Combined with Thread-embedding Acupuncture in the Treatment of Subclinical Hypothyroidism of Hashimoto's Thyroiditis Based on the Theory of Pre-disease Treat

Clinical Observation of Guyuan Moxibustion Combined with Thread-embedding Acupuncture in the Treatment of Subclinical Hypothyroidism of Hashimoto's Thyroiditis Based on the Theory of Pre-disease Treat

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006580
Enrollment
Unknown
Registered
2022-09-10
Start date
2022-09-09
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto's Thyroiditis

Interventions

Observation group:Guyuan moxibustion combined with thread-embedding acupuncture
Control group:L-T4

Sponsors

The Affiliated Hospital of Shandong University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Meet the Western diagnostic criteria of Hashimoto's thyroiditis and subclinical hypothyroidism; ? Age: 18 to 65 years old, male or female; ? Patients who have not received thyroid hormone preparations, immune modulators or other methods for the treatment of the disease within 1 month; ? Voluntarily participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: ? Pregnant or lactating women; ? Allergic constitution and previous clear related to external drug allergy; ? Patients with major organic diseases, such as serious liver and kidney diseases, cardiovascular diseases and infections; ? Central hypothyroidism, viral subacute thyroiditis, postpartum thyroiditis convalescence, hyperthyroidism treatment (radioiodine therapy and subtotal thyroidectomy) and drug induced subclinical hypothyroidism; ? Those who suffer from mental or psychological diseases and cannot cooperate with treatment.

Design outcomes

Primary

MeasureTime frame
Clinical efficacy;

Secondary

MeasureTime frame
SDS;Thyroid hormone levels;thyroid peroxidase antibody;SAS;thyroglobulin antibody;

Countries

China

Contacts

Public ContactYingxia Sun
sunyx75@126.com13335128670

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026